Clinical trials: Lupus Nephritis, open to volunteers
Lupus Nephritis, Diastolic Dysfunction
Diastolic Dysfunction and Inflammatory Biomarkers in Lupus Nephritis
This cross-sectional observational study aims to investigate the correlation between echocardiographic parameters of left ventricular diastolic dysfunction (E/A ratio, e', E/e' ratio, LAVI, and LVEF) and systemic inflammatory…
- Conditions
- Lupus Nephritis, Diastolic Dysfunction, Systemic Lupus Erythematosus, Heart Failure, Diastolic
- Trial name
- NCT07837544
- Volunteers
- 90 people
- Sponsor
- Assiut University
Lupus Nephritis
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every 12 hours) and (2)…
- Trial name
- PLUMM (NCT05538208)
- Testing
- Mycophenolate Mofetil
- Where
- 19 sites in United States
- Volunteers
- 105 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Lupus Nephritis, Primary Membranous Nephropathy
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in…
- Trial name
- NCT06557265
- Testing
- NKX019, Fludarabine, Cyclophosphamide
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 120 people
- Sponsor
- Nkarta, Inc.
Systemic Lupus Erythematosus, Lupus Nephritis
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- BAH242 (NCT06350110)
- Testing
- CD19- BCMA CAR-T cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Essen Biotech
SIOD, Cystinosis
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT…
- Conditions
- SIOD, Cystinosis, FSGS, SLE Nephritis
- Trial name
- NCT05508009
- Testing
- Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alice Bertaina
Lupus Nephritis, Systemic Lupus Erythematosus (SLE)
Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and Prednisolone
The goal of this clinical trial is to learn how different treatments affect immune cells in the kidney in people with active lupus nephritis (LN), a kidney manifestation of systemic lupus erythematosus (SLE).
- Trial name
- MAPLE (NCT07760480)
- Testing
- Kidney Biopsy, Voclosporin (LUPKYNIS), Blood, feces and urine sample collection
- Where
- Netherlands
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lupus Nephritis
The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis
This study investigated the effect of mycophenolate mofetil and cyclosphosphamide on lymphocyte subsets in patients with proliferative lupus nephritis.
- Trial name
- NCT02954939
- Testing
- MMF-MMF, CTX-AZA
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- The University of Hong Kong
Refractory Systemic Lupus Erythematosus, Refractory Lupus Nephritis
NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
This is an investigator-initiated, open-label, single-arm study to determine safety and preliminary efficacy of NK010 or NK042 in combination with rituximab (RTX) for the treatment of patients with refractory systemic lupus…
- Trial name
- NCT06676631
- Testing
- NK 010 or NK042, Rituximab
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Guangdong Provincial People's Hospital
Lupus Nephritis
Anti-alpha-actinin Antibodies and Lupus Nephritis Activity
Lupus nephritis (LN) develops in 30-60% of systemic lupus erythematosus (SLE) patients and remains a leading cause of morbidity, with 10-30% progressing to end-stage renal disease within 15 years.
- Trial name
- NCT07505576
- Testing
- renal biopsy, serum anti-alpha-actinin antibodies, CBC, serum creatinine and urea, estimated GFR, ESR, CRP, urine analysis, ANA, anti dsDNA, C3 & C4, serum albumin, 24-hrs urinary protein, and U. ACR
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Assiut University
Lupus Nephritis
Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients
Systemic Lupus Erthymatosous (SLE) is achronic inflammatory multi system auto immue disease characterized by pathogenic auto anti bodies production against nuclear structures (Bolouri et al.,2022), SLE affecting mainly woemn of…
- Trial name
- NCT06631404
- Testing
- renal doppler
- Where
- Egypt
- Volunteers
- 55 people
- Sponsor
- Sohag University
Lupus Nephritis (LN), SLE - Systemic Lupus Erythematosus
The Relation of Albumin/Globulin Ratio and Platelet/Albumin Ratio to Lupus Nephritis
Albumin/globulin ratio and platelet/albumin ratio as a predictive non-invasive biomarker for lupus nephritis (LN) presence and severity
- Conditions
- Lupus Nephritis (LN), SLE - Systemic Lupus Erythematosus, Biomarkers
- Trial name
- NCT07130448
- Volunteers
- 120 people
- Sponsor
- Assiut University
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B cell mediated autoimmune disease.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07305116
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Lupus Nephritis, Systemic Lupus Erythematosus
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory…
- Conditions
- Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus, Lupus Nephritis - WHO Class III
- Trial name
- RECLAIM-LN (NCT07570862)
- Testing
- FT819
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- Fate Therapeutics
Lupus Nephritis (LN), ANCA-Associated Glomerulonephritis
MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
This study will evaluate the safety and efficacy of MSC303 in patients with Immune glomerular diseases.
- Trial name
- MSC303 (NCT07000292)
- Testing
- Injection of MSC303
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Changzheng Hospital
Bone Mineral Density and Lupus Nephritis Activity
Predictors of Bone Mineral Density in Lupus Nephritis Activity
Our aim in this study is Correlation of histopathology of renal biopsy in SLE with lupus nephritis patients versus predictors of bone mineral density in active and inactive lupus nephritis
- Trial name
- NCT06837558
- Testing
- fibroblast growth factor 23
- Volunteers
- 100 people
- Sponsor
- Assiut University
Uromodulin, SLE
Uromodulin as a Biomarker in Lupus Nephritis
Evaluation of Uromodulin as a biomarker of renal histological activity/ Chronicity indices in lupus nephritis
- Trial name
- NCT07763834
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assiut University
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment
1. Study Design This is a single-center, prospective, randomized, controlled, exploratory clinical trial. The study is designed to evaluate and compare the efficacy and safety of two biologic-based induction regimens against…
- Trial name
- NCT07340463
- Testing
- Glucocorticoids, belimumab, Telitacicept
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Nanjing University School of Medicine
Lupus Nephritis, Membranous Nephropathy
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
Lupus nephritis (LN) is a frequent and severe complication of systemic lupus erythematosus, with important mortality and morbidity.
- Trial name
- OBLUMEN (NCT07721363)
- Testing
- Obinutuzumab
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Lupus Nephritis
CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
A Clinical Study of the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis.
- Trial name
- NCT06785519
- Testing
- CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- He Huang